{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:07:50Z","timestamp":1790050070517,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-030034"],"award-info":[{"award-number":["POCI-01-0145-FEDER-030034"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015620","name":"Institute for Bioengineering and Biosciences","doi-asserted-by":"publisher","award":["007317"],"award-info":[{"award-number":["007317"]}],"id":[{"id":"10.13039\/501100015620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jconrel.2021.07.035","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T02:46:07Z","timestamp":1627094767000},"page":"329-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer"],"prefix":"10.1016","volume":"337","author":[{"given":"Ana Rita","family":"Garizo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago P.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Fernardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina C.","family":"Barrias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e9nio M.","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/biom9010022","article-title":"Combination of cell-penetrating peptides with nanoparticles for therapeutic application: a review","volume":"9","author":"Silva","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0010","doi-asserted-by":"crossref","unstructured":"P. Agrawal, S. Bhalla, S.S. Usmani, S. Singh, K. Chaudhary, G.P. Raghava, A. Gautam, CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides, Nucleic Acids Res 44(D1) (2016) D1098\u2013103. https:\/\/doi.org\/10.1093\/nar\/gkv1266.","DOI":"10.1093\/nar\/gkv1266"},{"issue":"11","key":"10.1016\/j.jconrel.2021.07.035_bb0015","first-page":"2171","article-title":"Cancer targeting peptides","volume":"76","author":"Kalmouni","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/17425247.2020.1739646","article-title":"Advances in the use of cell penetrating peptides for respiratory drug delivery","volume":"17","author":"Gomes Dos Reis","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0025","doi-asserted-by":"crossref","unstructured":"K. Hoffmann, N. Milech, S.M. Juraja, P.T. Cunningham, S.R. Stone, R.W. Francis, M. Anastasas, C.M. Hall, T. Heinrich, H.M. Bogdawa, S. Winslow, M.N. Scobie, R.E. Dewhurst, L. Florez, F. Ong, M. Kerfoot, D. Champain, A.M. Adams, S. Fletcher, H.M. Viola, L.C. Hool, T. Connor, B.A.C. Longville, Y.F. Tan, K. Kroeger, V. Morath, G.A. Weiss, A. Skerra, R.M. Hopkins, P.M. Watt, A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery, Sci Rep 8(1) (2018) 12538. https:\/\/doi.org\/10.1038\/s41598-018-30790-2.","DOI":"10.1038\/s41598-018-30790-2"},{"issue":"2","key":"10.1016\/j.jconrel.2021.07.035_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/nnm-2018-0326","article-title":"Controlling endosomal escape using nanoparticle composition: current progress and future perspectives","volume":"14","author":"Cupic","year":"2019","journal-title":"Nanomedicine (Lond)"},{"issue":"4","key":"10.1016\/j.jconrel.2021.07.035_bb0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0169-409X(02)00021-2","article-title":"The origin of pegnology","volume":"54","author":"Davis","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2021.07.035_bb0040","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/psc.2672","article-title":"Cell penetration: scope and limitations by the application of cell-penetrating peptides","volume":"20","author":"Reissmann","year":"2014","journal-title":"J. Pept. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2021.07.035_bb0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2021.07.035_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11060280","article-title":"Recent Progress in the development of poly(lactic-co-glycolic acid)-based nanostructures for Cancer imaging and therapy","volume":"11","author":"Kim","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0055","article-title":"Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications","volume":"7","author":"Martins","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","article-title":"Recent applications of PLGA based nanostructures in drug delivery","volume":"159","author":"Mir","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"7","key":"10.1016\/j.jconrel.2021.07.035_bb0065","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1039\/c2cs15294k","article-title":"Surface functionalization of nanoparticles for nanomedicine","volume":"41","author":"Mout","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.jconrel.2021.07.035_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123871","article-title":"Perturbing the dynamics and Organization of Cell Membrane Components: a new paradigm for Cancer-targeted therapies","volume":"19","author":"Bernardes","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2021.07.035_bb0075","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/15384101.2016.1172147","article-title":"Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased beta1 integrin-mediated adhesion","volume":"15","author":"Bernardes","year":"2016","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.jconrel.2021.07.035_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4161\/bioe.29266","article-title":"Bacterial proteins and peptides in cancer therapy: today and tomorrow","volume":"5","author":"Chakrabarty","year":"2014","journal-title":"Bioengineered"},{"issue":"2","key":"10.1016\/j.jconrel.2021.07.035_bb0085","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1158\/0008-5472.CAN-08-2932","article-title":"Noncationic peptides obtained from azurin preferentially enter cancer cells","volume":"69","author":"Taylor","year":"2009","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2021.07.035_bb0090","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1462-5822.2005.00567.x","article-title":"Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity","volume":"7","author":"Yamada","year":"2005","journal-title":"Cell. Microbiol."},{"issue":"10","key":"10.1016\/j.jconrel.2021.07.035_bb0095","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1535-7163.MCT-09-0444","article-title":"A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells","volume":"8","author":"Yamada","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2021.07.035_bb0100","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/bjc.2013.266","article-title":"p28, a first in class peptide inhibitor of cop1 binding to p53","volume":"108","author":"Yamada","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.jconrel.2021.07.035_bb0105","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1021\/mp400221r","article-title":"p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation","volume":"10","author":"Yamada","year":"2013","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2021.07.035_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10456-011-9220-6","article-title":"A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2","volume":"14","author":"Mehta","year":"2011","journal-title":"FAK and Akt, Angiogenesis"},{"issue":"8","key":"10.1016\/j.jconrel.2021.07.035_bb0115","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-15-2355","article-title":"p28-mediated activation of p53 in G2-M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy","volume":"76","author":"Yamada","year":"2016","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2021.07.035_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/a-0654-4952","article-title":"The enhanced cytotoxic effects of the p28-Apoptin chimeric protein as a novel anti-Cancer agent on breast Cancer cell lines","volume":"69","author":"Noei","year":"2019","journal-title":"Drug Res (Stuttg)"},{"issue":"12","key":"10.1016\/j.jconrel.2021.07.035_bb0125","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1021\/acs.biomac.0c01216","article-title":"Azulitox-a Pseudomonas aeruginosa P28-derived Cancer-cell-specific protein photosensitizer","volume":"21","author":"Raber","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0130","unstructured":"M. Soleimani, H. Mirmohammmad Sadeghi, A. Jahanian-Najafabadi, A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines, Iran J Pharm Res 18(2) (2019) 735\u2013744. 10.22037\/ijpr.2019.2392."},{"issue":"9","key":"10.1016\/j.jconrel.2021.07.035_bb0135","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/neuonc\/now047","article-title":"Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: a pediatric brain tumor consortium study","volume":"18","author":"Lulla","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0140","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/bjc.2013.74","article-title":"A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours","volume":"108","author":"Warso","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pulmoe.2020.02.005","article-title":"Conquering lung cancer: current status and prospects for the future","volume":"26","author":"Pirker","year":"2020","journal-title":"Pulmonology"},{"issue":"6","key":"10.1016\/j.jconrel.2021.07.035_bb0150","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"9352","key":"10.1016\/j.jconrel.2021.07.035_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jconrel.2021.07.035_bb0160","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.07.035_bb0165","doi-asserted-by":"crossref","first-page":"9090325","DOI":"10.1155\/2017\/9090325","article-title":"Targeted therapeutic nanoparticles: an immense promise to fight against Cancer","volume":"2017","author":"Jahan","year":"2017","journal-title":"J Drug Deliv"},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0170","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-017-3427-1","article-title":"The potential of multi-compound nanoparticles to bypass drug resistance in cancer","volume":"80","author":"Da Silva","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jat.3476","article-title":"Potential applications and human biosafety of nanomaterials used in nanomedicine","volume":"38","author":"Su","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.jconrel.2021.07.035_bb0180","doi-asserted-by":"crossref","first-page":"198175","DOI":"10.1155\/2015\/198175","article-title":"The chemistry of bioconjugation in nanoparticles-based drug delivery system","volume":"2015","author":"Werengowska-Cie\u0107wierz","year":"2015","journal-title":"Advances in Condensed Matter Physics"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0185","doi-asserted-by":"crossref","unstructured":"J. das Neves, B. Sarmento, Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides, Acta Biomater 18 (2015) 77\u201387. https:\/\/doi.org\/10.1016\/j.actbio.2015.02.007.","DOI":"10.1016\/j.actbio.2015.02.007"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.07.035_bb0195","doi-asserted-by":"crossref","unstructured":"N.S. Ks, G.P. K, R. Verma, P. Ananthakrishna, L. Kumar, Validation of HPLC Method for Quantitative Determination of Gefitinib in Polymeric Nanoformulation, Pharmaceutical Chemistry Journal 51(2) (2017) 159\u2013163. https:\/\/doi.org\/10.1007\/s11094-017-1575-6.","DOI":"10.1007\/s11094-017-1575-6"},{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1165\/ajrcmb.10.1.7507342","article-title":"CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells","volume":"10","author":"Cozens","year":"1994","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.07.035_bb0205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.019","article-title":"Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis","volume":"266","author":"Costa Verdera","year":"2017","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2021.07.035_bb0210","first-page":"421","article-title":"N:NIH(S)-nu\/nu mice with combined immunodeficiency: a new model for human tumor heterotransplantation","volume":"65","author":"Azar","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.08.064","article-title":"Nanoprecipitation process: from encapsulation to drug delivery","volume":"532","author":"Martinez Rivas","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"39","key":"10.1016\/j.jconrel.2021.07.035_bb0220","doi-asserted-by":"crossref","first-page":"22182","DOI":"10.1039\/C8RA02095G","article-title":"Manipulating extracellular tumour pH: an effective target for cancer therapy","volume":"8","author":"Hao","year":"2018","journal-title":"RSC Adv."},{"issue":"23","key":"10.1016\/j.jconrel.2021.07.035_bb0225","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1080\/15384101.2019.1674053","article-title":"IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function","volume":"18","author":"Liang","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0230","doi-asserted-by":"crossref","first-page":"120218","DOI":"10.1016\/j.biomaterials.2020.120218","article-title":"Chitosan\/gamma-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer","volume":"257","author":"Castro","year":"2020","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0235","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.bbamcr.2013.01.029","article-title":"p300\/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles","volume":"1833","author":"Kaur","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0240","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.2147\/DDDT.S275123","article-title":"Co-delivery anticancer drug nanoparticles for synergistic therapy against lung Cancer cells","volume":"14","author":"Shen","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.jconrel.2021.07.035_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and Polydispersity index on the clinical applications of Lipidic Nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2018.03.002","article-title":"Insights into maleimide-thiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targeting","volume":"282","author":"Martinez-Jothar","year":"2018","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2021.07.035_bb0255","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cplu.202000496","article-title":"Development of high-drug-loading nanoparticles","volume":"85","author":"Liu","year":"2020","journal-title":"Chempluschem"},{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1166\/jbn.2019.2670","article-title":"Nanoparticle-based drug delivery Systems for Enhanced Tumor-Targeting Treatment","volume":"15","author":"Li","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"issue":"17","key":"10.1016\/j.jconrel.2021.07.035_bb0265","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1039\/C4CS00487F","article-title":"Nanoparticle colloidal stability in cell culture media and impact on cellular interactions","volume":"44","author":"Moore","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2021.07.035_bb0270","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.msec.2017.12.036","article-title":"Recent advances of PLGA micro\/nanoparticles for the delivery of biomacromolecular therapeutics","volume":"92","author":"Ding","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"13","key":"10.1016\/j.jconrel.2021.07.035_bb0275","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1080\/15384101.2018.1489178","article-title":"Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs","volume":"17","author":"Bernardes","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0280","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-cellbio-100617-062737","article-title":"Caveolae: Structure","volume":"34","author":"Parton","year":"2018","journal-title":"Function, and Relationship to Disease, Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0285","doi-asserted-by":"crossref","unstructured":"L.R. Bollu, R.R. Katreddy, A.M. Blessing, N. Pham, B. Zheng, X. Wu, Z. Weihua, Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation, Oncotarget 6(33) (2015) 34992\u20135003. 10.18632\/oncotarget.5252.","DOI":"10.18632\/oncotarget.5252"},{"issue":"21","key":"10.1016\/j.jconrel.2021.07.035_bb0290","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1016\/j.biomaterials.2011.03.031","article-title":"Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides","volume":"32","author":"Li","year":"2011","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2021.07.035_bb0295","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ejps.2012.07.002","article-title":"Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery","volume":"47","author":"Chen","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.07.035_bb0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2014.06.051","article-title":"Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer","volume":"192","author":"Wang","year":"2014","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2021.07.035_bb0305","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1002\/jps.24649","article-title":"Twin-arginine translocation peptide conjugated Epirubicin-loaded nanoparticles for enhanced tumor penetrating and targeting","volume":"104","author":"Zhang","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0310","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11095-019-2602-y","article-title":"Efficacy of surface-modified PLGA nanoparticles as a function of cervical Cancer type","volume":"36","author":"Sims","year":"2019","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2021.07.035_bb0315","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/21691401.2017.1360325","article-title":"Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')2 and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma","volume":"46","author":"Jin","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0320","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.intimp.2018.07.006","article-title":"Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines","volume":"62","author":"Shahbazi","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2021.07.035_bb0325","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijpharm.2007.04.002","article-title":"Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors","volume":"341","author":"Bergman","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2021.07.035_bb0330","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10717544.2017.1384862","article-title":"In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer","volume":"24","author":"Ni","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.jconrel.2021.07.035_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2018.02.024","article-title":"Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer","volume":"275","author":"Jeannot","year":"2018","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2021.07.035_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090469","article-title":"Development and evaluation of multifunctional poly(lactic-co-glycolic acid) nanoparticles embedded in Carboxymethyl beta-Glucan porous microcapsules as a novel drug delivery system for Gefitinib","volume":"11","author":"Li","year":"2019","journal-title":"Pharmaceutics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921003783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921003783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:59:05Z","timestamp":1772737145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921003783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":68,"alternative-id":["S0168365921003783"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}